Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series

Pessôa‐Pereira, Danielle; Medeiros, Manoel; Lima, Virna Mendonça Sampaio; Silva, Joaquim Custódio da; Cerqueira, Taíse Lima de Oliveira; Silva, Igor Campos da; Fonseca, Luciano Espinheira; Sampaio, Luiz José Lobão; Lima, Cláudio Rogério Alves de; Ramos, Helton Estrela

doi:10.20945/2359-3997000000120

Cited by 22 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No correlation was found between BRAF-V600E mutations and the clinicopathological features, including age, gender, LNM, bilateral involvement, vascular tumor thrombus, capsule invasion, foci number, nerve invasion or maximum tumor diameter, while BRAF-V600E expression was signi cantly correlated only with intralobular dissemination in this study (P < 0.05). Our nding was not consistent with that of the study by Pessoa, which demonstrated the independent correlation of BRAF-V600E with age and HT 13 .…”

Section: Discussioncontrasting

confidence: 99%

Conventional Papillary Thyroid Carcinoma With Intralobular Lymphatic Dissemination Shows More Aggressive Features

Lei

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To investigate the invasive capability and other clinicopathological features of conventional papillary thyroid carcinoma (CVPTC) with intralobular lymphatic dissemination.Methods: Seventy-three CVPTC patients receiving total thyroidectomy were analyzed in this study. The expression of BRAF-V600E, D2-40 and CD31 in all thyroid samples was detected by immunohistochemical staining (IHC). The results were evaluated by two pathologists and were statistically analyzed. In addition, the rate of positive BRAF-V600E expression and the clinical invasiveness of CVPTC with intralobular dissemination (ID-CVPTC), multiple primary CVPTC (MP-CVPTC) and single focus CVPTC (SF-CVPTC) were evaluated. The correlation between BRAF-V600E expression, lymphatic vessel density (LVD), microvessel density (MVD) and the clinicopathological characteristics of CVPTC were assessed.Results: Twenty-five ID-CVPTC, 17 MP-CVPTC and 31 SF-CVPTC cases were included in this study. The positive expression rate of BRAF-V600E in ID-CVPTC (92.0%) was significantly higher than that in MP-CVPTC (70.6%) and SF-CVPTC (71.0%), while no significant difference in expression between MP-CVPTC and SF-CVPTC was detected (P > 0.05). The expression of BRAF-V600E was not related to clinicopathological features, including age, gender, lymph node metastasis (LNM), bilateral involvement, presence of vascular tumor thrombus, capsule invasion, nerve invasion or the maximum tumor diameter (P > 0.05). The LVD in the ID-CVPTC group (9.74 ± 2.98) was higher than that in the non-ID-CVPTC group (7.46 ± 2.5) (P < 0.05). Compared with cases without adenolobar dissemination, ID-CVPTC was associated with a younger age, higher LNM rate, and increased capsule and vessel invasiveness (P < 0.05).Conclusions: ID-CVPTC shows more aggressive features, and intralobular lymphatic dissemination may be a potential biological indicator of poor prognosis.

show abstract

Section: Discussioncontrasting

confidence: 99%

Conventional Papillary Thyroid Carcinoma With Intralobular Lymphatic Dissemination Shows More Aggressive Features

Lei

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…We also have shown a significantly higher frequency of BRAF V600E mutation in patients with ages younger than 55 years. Other studies [43][44][45] have shown a higher frequency BRAF V600E mutation among patients with ages higher than 55 years. We believe that this difference in the age pattern of BRAF V600E mutation is mainly due to the differences in patients samples between ours and these studies; as most of our PTC samples (70%) are from patients with ages younger than 55 years (Fig 2).…”

Section: Plos Onementioning

confidence: 85%

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

et al. 2020

View full text Add to dashboard Cite

Background Papillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm comprising 80-90% of all thyroid malignancies. Molecular changes in thyroid follicular cells are likely associated with the development of PTC. Mutations in serine/threonine-protein kinase (BRAF) and Rat sarcoma viral oncogene homolog (RAS) are commonly seen in PTC. Methods In total, 90 cases of PTC are randomly selected from archive paraffin blocks and 10μm sections were cut and processed for DNA extraction. BRAF V600E mutation and 8 types of KRAS mutations were investigated using Real Time PCR. Results BRAF V600E mutation was identified in 46% of PTC while KRAS mutations were seen in 11% of PTC. There was significant correlation between BRAF V600E mutation and PTC larger than 5cm in diameter, positive surgical margin and lymph node metastasis. BRAF V600E mutation was significantly higher in patients with less than 55-year of age than those more than 55-year of age. BRAF V600E mutation was significantly higher in patients with family history of thyroid cancer than those without. There was no significant difference in BRAF V600E mutation between males and females, PTC classic and follicular variants, unifocal and multifocal PTC. There was a significant higher percentage of BRAF V600E mutation in classic PTC than papillary microcarcinoma variant. There was no significant age, gender, histologic type, tumor size, lymph node metastasis, tumor focality, and surgical margin status differences between KRAS mutated and non-mutated PTC.

show abstract

“…So far, we have only seen one case reported regarding BRAF mutation (c.1799 T>A;1801_1812del) in primary SCC of the thyroid (27). As we know that BRAF mutations, especially, BRAF V600E mutation is the most common molecular genetic change in PTC (28)(29)(30)(31)(32). Therefore, we believe that the SCC in the metastatic foci of this case may be evolved from the tall-cell subtype of PTC.…”

Section: Discussionmentioning

confidence: 75%

On the basis of Hashimoto's thyroiditis, to form papillary thyroid carcinoma, metastasized and then to de-differentiate into poorly differentiated squamous cell carcinoma

Huang

Ren

Zhu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Thyroid squamous cell carcinoma is very rare. At present, it is limited to case reports. Since the thyroid follicular epithelium is the non-squamous epithelium, how primary squamous cell carcinoma(SCC) of the thyroid occurs is still a controversial issue. Hashimoto's thyroiditis(HT) is considered to be an independent risk factor for thyroid cancer, under the basis of HT, how tumor cells evolve and develop to papillary thyroid carcinoma(PTC), and particularly to de-differentiate into SCC is elusive.Patient: We report a 72-year-old female patient who developed multiple subtypes of PTC on a basis of HT, and finally to de-differentiate into SCC within the local foci of lymph node metastasis. Summary: We found that there was a variety of sub-types of PTC in this patient in the background of HT. SCC was found within local lymph node metastasis. Pathomorphology, immunohistochemistry, and molecular pathology have confirmed that SCC was derived from PTC, and then developed into poorly differentiated SCC and/or anaplastic carcinoma. We also conducted a comprehensive literature review.Conclusions: Thyroid SCC is derived from PTC and de-differentiated into poor differentiated SCC and/or anaplastic carcinoma, which is the result of the continuous evolution of PTC. It is suggested that the prognosis of the patient is very poor.

show abstract

Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series

Cited by 22 publications

References 37 publications

Conventional Papillary Thyroid Carcinoma With Intralobular Lymphatic Dissemination Shows More Aggressive Features

Conventional Papillary Thyroid Carcinoma With Intralobular Lymphatic Dissemination Shows More Aggressive Features

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates

On the basis of Hashimoto's thyroiditis, to form papillary thyroid carcinoma, metastasized and then to de-differentiate into poorly differentiated squamous cell carcinoma

Contact Info

Product

Resources

About